Economic evaluation of FENO measurement in diagnosis and 1-year management of asthma in Germany  by Berg, Jenny & Lindgren, Peter
ARTICLE IN PRESS
Respiratory Medicine (2008) 102, 219–2310954-6111/$ - see fro
doi:10.1016/j.rmed.
Corresponding au
E-mail address: jEconomic evaluation of FENO measurement
in diagnosis and 1-year management of asthma
in Germany
Jenny Berga,, Peter Lindgrena,bai3 Innovus, Vasagatan 38, SE-111 20 Stockholm, Sweden
bInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Received 18 December 2006; accepted 20 September 2007
Available online 29 October 2007KEYWORDS
Asthma;
Cost-effectiveness;
Diagnosis;
Exhaled nitric oxide;
Managementnt matter & 2007
2007.09.008
thor. Tel.: +46 8 5
enny.b@healthecoSummary
Objective: Fractional exhaled nitric oxide (FENO) is a marker for airway inflammation in
asthma. The objective of this study was to assess the cost-effectiveness of FENO
measurement at a reimbursement price of h34 using NIOX MINOs, a portable non-invasive
FENO monitor, in asthma diagnosis and management.
Methods: Two decision trees were constructed to capture the different alternatives and
consequences in asthma diagnosis and management, comparing FENO measurement against
standard diagnostics and treatment guidelines. The impact of asthma management with
FENO measurement on resource use and health outcomes was evaluated over a 1-year
timeframe. A German payer perspective was chosen. Effectiveness was measured in
quality-adjusted life-years.
Results: Asthma diagnosis based on FENO measurement results in a cost of h38 per patient
compared with h26 for standard diagnostics. In mild to severe patients, asthma
management with FENO measurement instead of standard guidelines results in cost-savings
of h30 per patient and year. In a more severe population, management with FENO
measurement would save costs of h160 per patient.
Conclusion: Asthma diagnosis based on FENO measurement alone (exemplified with NIOX
MINO) costs h12 more per patient than standard diagnostic methods, while offering
improved accuracy. The use of FENO measurement in treatment decisions is less costly than
asthma management based on standard guidelines and provides similar health benefits.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
45 28 547; fax: +46 8 545 28 549.
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Asthma is a chronic pulmonary disease characterised by
reversible airway obstruction, airway inflammation and
increased responsiveness of the airways to different stimuli,
leading to exacerbations. The prevalence of asthma is
estimated to lie around 5–10% worldwide, with children
being more commonly affected than adults. There is also a
large variation in prevalence rates between and within
countries.1 In Germany, a recent cost-of-illness study based
on health insurance data estimated the total direct and
indirect costs of asthma at h2.7 bn in 1999, as well as a
prevalence rate of 6.3%.2
Asthma diagnosis generally consists of patient history,
clinical examination, lung function (spirometry) and hyper-
responsiveness testing. Techniques that monitor the inflam-
matory state of the airways, such as eosinophil count in the
sputum or measurement of fractional exhaled nitric oxide
(FENO), can be used for both diagnosis and management of
asthma.3–5 There has been a range of studies on the
relationship between FENO, other inflammatory markers,
disease activity and treatment response.6–14 FENO correlates
well with airway eosinophilia in induced sputum, biopsy
material and bronchoalveolar lavage fluid.7–10 Moreover,
treatment with inhaled steroids leads to a fall in FENO
levels.11,12 Specifically, both single measurements and
changes of FENO have positive predictive values ranging
from 80% to 90% for predicting and diagnosing loss of control
following steroid withdrawal.13
Until recently, FENO measurement was based on chemilu-
minescence NO analysis. Over the last years, techniques
have been developed that can measure FENO not only in a
research setting, but also in clinical practice. NIOX MINOs
Airway Inflammation Monitor (Aerocrine AB, Solna, Sweden)
is a portable, non-invasive airway inflammation monitor for
measuring FENO levels that uses electrochemical sensors and
has the benefit of being fast, independent of patient
technique and relatively inexpensive.15 This makes it unique
compared with other ways of measuring airway inflamma-
tion, such as sputum induction or bronchoalveolar lavage.16
Moreover, it is less costly than previously available sta-
tionary devices and has thus the potential to be used
routinely in clinical practice.
In line with increasing pressure on healthcare budgets,
new therapeutic applications not only need to show clinical
efficacy but also cost-effectiveness. It is, therefore, of
interest to evaluate the cost-effectiveness of the NIOX MINO
device, which is new to the German market, from a local
healthcare payer perspective. The objective of this study
was thus to assess the cost-effectiveness of FENO measure-
ment with NIOX MINO in the diagnosis of asthma and in
optimising asthma management using the expected reim-
bursement price of the device. It is to our knowledge the
first economic evaluation of the use of FENO in the diagnosis
and management of asthma.Methods
Economic evaluations involve a comparative analysis of
alternative courses of action in terms of their costs and
consequences in a given patient population. By assessingcosts and outcomes on a patient level, the economic
efficiency of alternatives can be compared. Other types of
analysis, e.g. budget impact models, focus specifically on
the financial consequences of a new intervention in a given
setting, which can answer questions about affordability, but
not regarding cost-effectiveness. Decision analytic model-
ling is used to represent reality and to incorporate evidence
from different sources, facilitating translation into esti-
mates of the costs and effects of the examined alternatives.
It also provides a framework for decision-making under
uncertainty.17
The cost-effectiveness models
Asthma diagnosis and management are characterised by
different competing alternatives and outcomes. The con-
sequences of an improved diagnosis cannot necessarily be
directly linked to treatment outcomes, due to lack of data
on e.g. the impact of an incorrect diagnosis on longer-term
outcomes such as exacerbations or hospitalisations. There-
fore, two decision trees were developed in TreeAge, which
capture the different diagnosis and treatment options for
asthma. A decision tree is a structured representation of
alternative choices, probabilities of subsequent events and
ultimate outcomes. For economic evaluations, clinical data
are combined with the costs and effects of different events
to calculate the cost-effectiveness of different treatment
strategies.18 When choosing the base case for evaluation, it
is important to reflect the available clinical evidence as
closely as possible, e.g. in the choice of comparators and
patient population. In both models, we have used con-
servative assumptions and sought to include all relevant
data from clinical studies and asthma guidelines. Where
evidence is not yet fully available, we have chosen to
evaluate potential variations in clinical practice through
scenario analysis.
Diagnosis
If patient history and clinical examination (generally by a
primary care physician) suggest possible asthma, further
diagnostic testing is indicated, which in Germany is often
conducted by office-based lung specialists (in particular for
moderate and severe patients). In the major clinical study
on diagnostic accuracy of different asthma tests,19 patients
had been referred by their family practitioner for investiga-
tion of possible asthma, which can thus be seen to
correspond to clinical practice in Germany.
The detailed available clinical studies on FENO compare
the measure individually against different diagnostic meth-
ods, rather than as an add-on to existing tests. Although
evidence exists that shows improved diagnostic accuracy
when FENO measurement is combined with spirometry,
20
these data are currently only published as a review.
Therefore, the base case analysis for the impact on diagnosis
uses the most detailed clinical study available, which
compares FENO measurement separately against standard
diagnostics, while possible combinations in eventual clinical
practice are assessed in a separate scenario. Moreover, in
Germany, body plethysmography (an airtight chamber
used for measuring e.g. thoracic gas volume and airway
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Economic evaluation of FENO measurement in asthma 221resistance) is often part of the standard diagnostic work-up.
However, no clinical data on its sensitivity and specificity
compared with FENO measurement could be identified. The
following tests were thus included as commonly used
methods based on local market information, German asthma
guidelines3 and the availability of clinical data:Fig
tre
me
MIN
cos
un
senspirometry (relative frequency weight 70%);
 reversibility testing (relative frequency weight 20%);
 bronchial provocation (relative frequency weight 7%);
 sputum eosinophil count (relative frequency weight 3%).While patients may receive several of these tests, we
have chosen to allocate mutually exclusive weights in the
combined test arm, which give an indication of the relative
use of each examination. Otherwise we would need to make
assumptions about the sensitivity and specificity of the likely
combinations, which would introduce a greater degree of
uncertainty into the analysis. In clinical practice, it can be
expected that FENO measurement will not replace lung
function tests, but rather be used in conjunction with e.g.
spirometry (as outlined above). Since the findings on theAsthma
p
Non-asthma
1
NIOX MINO
c_test=if(strategy=1; 34; 42)
sensitivity=if(strategy=1; 0.88; 0.94)
specificity=if(strategy=1; 0.79; 0.93)
Spirometry
if (sce
c_test=8
sensitivity=0.3
specificity=1
Reversibility
if (sce
c_test=22
sensitivity=0.2
specificity=1
Bronchial p
if (scen
c_test=106
sensitivity=0.8
specificity=0.8
Sputum eos
if (scen
c_test=106
sensitivity=0.8
specificity=0.8
Spirometry+
if (sc
c_test=112
sensitivity=0.8
specificity=1
Standard diagnostics
Choose
c_outpatient=20
prevalence=0.36
scenario=1
strategy=1
ure 1 Structure of economic model for evaluation of FENO mea
e represents the different results following diagnosis with FENO ma
thods. For each of the standard diagnostics, a dynamic copy (clo
O. Results are influenced by the underlying disease prevalence,
t of outpatient visit (primary care physician or pulmonologist), c_
derlying patient population, scenario: main comparator (1 ¼ st
sitivity of test, specificity: specificity of test, strategy: NIOX MINcombined test are currently only published as a review, we
have tested this in a separate scenario using information
from Smith and Taylor.20 In a different, more hypothetical
scenario, we evaluate FENO measurement against spirometry
and bronchoprovocation as a more direct comparator that
tests both lung function and airway hyperresponsiveness.
Figure 1 illustrates the tree structure for the diagnosis
analysis. Each test is applied to the same population of
possible asthma patients, with the proportion of true
asthma cases based on the underlying study. Each patient
may receive a true or false diagnosis, which is determined
by the test sensitivity and specificity. If a patient has
received a false diagnosis, we have made the conservative
assumption that at least one additional outpatient visit is
required to receive a correct diagnosis. Although it is likely
that misdiagnosis is related to higher costs, e.g. due to
wrong medication, further specialist or even hospital visits,
no supporting evidence to quantify these costs could be
found in the literature. In absence of such data, any further
assumptions on the cost of misdiagnosis could represent an
overestimation, which in turn, would also lead to an
overestimation of the cost savings to be gained with a
diagnosis using FENO measurement.True positive
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Figure 2 Structure of economic model for evaluation of FENO management measurement (NIOX MINO) in asthma management. Note: The decision tree represents the key outcomes
in asthma management, focusing on successful control and exacerbations. These are related to different levels of medical resource use and quality of life. For standard management,
a dynamic copy (clone) of the possible events is linked to the branches after FENO measurement with NIOX MINO. c_ICS: cost of maintenance inhaled steroid, c_inpatient: cost of
inpatient admission for asthma, c_LABA: cost of maintenance long-acting beta-agonist, c_monitor: cost of test used for monitoring management, c_oral: cost of oral steroid for
rescue therapy, c_outpatient: cost of outpatient visit (primary care physician or pulmonologist), c_SABA: cost of short-acting beta-agonist for rescue therapy, freq: number of
monitoring visits/tests per year, no_exac: average number of severe exacerbations per year, prob_exac: probability of exacerbation during one year, prob_hosp: probability of being
hospitalised due to severe exacerbation, prob_outp: % of severe exacerbations requiring outpatient visit, red_ICS: relative inhaled steroid dose, relrisk_exac: relative risk of
exacerbation with management strategy, relrisk_hosp: relative risk of hospitalisation due to exacerbation with management strategy, severe: dummy for moderate-severe
population, severe_exac: % of patients with exacerbation that is severe (requiring oral steroid or hospitalisation), strategy: base case comparator (1 ¼ spirometry only; 0 ¼ NIOX
MINO+spirometry), util_control: utility for good control, util_moderate: utility for moderately reduced control, util_poor: utility for poor control.
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For the analysis of the impact of FENO measurement on the
management of asthma, the available data allows compar-
ison against standard guidelines (British Thoracic Society,
BTS,4 and Global Initiative for Asthma, GINA21), which
generally consist of monitoring based on spirometry and
degree of b-agonist use. Thus, a decision tree has been
constructed that captures the impact of FENO measurement
vs. spirometry on asthma outcomes over a 1-year timeframe
(to reflect the majority of available clinical evidence).
b-agonist use is not included as a separate test, as this falls
under standard monitoring visits. The decision tree is shown
in Figure 2.
Although the patient populations and settings vary slightly
across the relevant clinical studies, the main analysis covers
patients with mild to severe asthma who are seen in both
primary and secondary care. On the basis of existing
treatment guidelines for Germany,3 we have assumed that
an ‘‘average’’ patient will receive inhaled corticosteroids
(ICS) and long-acting b-agonists as maintenance therapy. In
both management arms, patients can either be successfully
controlled by their therapy or suffer an exacerbation.
Exacerbations have been divided into mild, moderate and
severe to capture the different levels of resource use. In line
with several clinical studies used,22,23 we have defined
severe exacerbations as loss of asthma control requiring oral
steroids, while mild or moderate exacerbations only require
short-acting b-agonists. Severe exacerbations are further
separated into those leading to hospitalisation and those
that can be managed in an outpatient setting or by patients
themselves. Average numbers of exacerbations for overall
and more severe patients are applied to the relevant
resources in the exacerbation arm.
Quality-adjusted life-years (QALYs) represent a common
effectiveness measure in economic evaluations, as they
capture the effect of treatment on both survival and
quality of life (QoL) and allow comparison of results
across different disease areas. Life-years are adjusted for
QoL by using utility weights that measure the relative
preference for different health states or outcomes.24 Since
utility values are available for different levels of asthma
control, it was possible to use QALYs as an outcome in our
analysis.Table 1 Sensitivity and specificity of diagnostic tests.
Test Sensitivity
Value (%)
FENO (flow rate 50ml/s; 420 ppb) 88
FENO (flow rate 50ml/s; 433 ppb)+spirometry 94
Spirometry* 35
Reversibility test* 24
Bronchial provocation 88
Sputum eosinophil count 86
Spirometry+bronchoprovocation 88
Note: *Using sensitivity and specificity of the best performing test wEvent probabilities
Diagnosis
The sensitivity and specificity for each test were mainly
derived from a study by Smith et al.,19 which included 47
patients between 8 and 75 years in a hospital clinic. Asthma
diagnosis was determined through the combination of
symptom history, a positive test for bronchial hyperrespon-
siveness and/or a positive bronchodilator response. Since
the study analysed spirometric and reversibility measures
separately, the accuracy of the best performing measure
was used for spirometry and reversibility testing as overall
methods. Diagnostic accuracy for bronchial provocation
tests was taken from a study by Berkman et al.,25 using
the results for methacholine as the most commonly
performed test of airway hyperresponsiveness. To compare
FENO measurement directly against a diagnostic method
covering both lung function and airway hyperresponsiveness
and to reduce uncertainty around the frequency of use of
different tests, the alternative of spirometry together with
bronchoprovocation was also included in the model. Its
sensitivity and specificity was assumed to have the highest
sensitivity and specificity values of the individual tests. The
accuracy data for the different tests, as well as the
underlying distributions for the stochastic sensitivity analy-
sis, are summarised in Table 1. These were based on the
diagnoses and underlying disease prevalence reported in the
relevant studies.19,20,25 The proportion of true asthma
patients in the tested population was assumed to be 36%,
the same as in the study by Smith et al.19Management
A number of studies have prospectively evaluated the use of
FENO to assist in management decisions for asthma, several
of which were randomised controlled trials.12,22,23,26 Two of
these studies22,23 used sputum eosinophil count as an
inflammatory marker. An observational study of 566 asth-
matics recently showed that sputum cell eosinophils and
FENO concentration are significantly correlated across a wide
range of patients, provided they are non-smokers.27 There-
fore, the results of the studies by Green et al.22 and Jayaram
et al.23 can also be applied to FENO as a diagnostic tool in
asthma management.Specificity Source
Distribution Value (%) Distribution
b (n ¼ 16) 79 b (n ¼ 28) 19
b (n ¼ 16) 93 b (n ¼ 28) 20
b (n ¼ 17) 100 b (n ¼ 30) 19
b (n ¼ 17) 100 b (n ¼ 29) 19
b (n ¼ 41) 87 b (n ¼ 44) 25
b (n ¼ 14) 88 b (n ¼ 26) 19
b (n ¼ 17) 100 b (n ¼ 30) 19,25
ithin each group.
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Table 2 Parameters used in the asthma management model.
Value Distribution Source
Baseline event probabilities
Exacerbation risk during one year 71% b (n ¼ 52, r ¼ 37) 23
Proportion of exacerbations that are severe 23% N/a 23
Hospitalisation due to severe exacerbation 23% N/a 22
Proportion of severe exacerbations requiring outpatient visits 75% b (n ¼ 425, r ¼ 319) 28
Average number of severe exacerbations per year (overall population) 2 Fixed 23,29
Average number of severe exacerbations per year (moderate-severe population) 4 Fixed 22
Impact of FENO management
ICS dose (mg/day) 26
Standard arm 641 Normal (SD ¼ 59)
FENO arm 370 Normal (SD ¼ 55)
Risk of exacerbation 23
Standard arm 71% b (n ¼ 52, r ¼ 37)
FENO arm 52% b (n ¼ 50, r ¼ 26)
Risk of hospitalisation due to severe exacerbation 22
Standard arm 18% b (n ¼ 34, r ¼ 6)
FENO arm 3% b (n ¼ 34, r ¼ 1)
Note: SD ¼ standard deviation.
Baseline rates are taken from the standard management arm in the stochastic simulations.
J. Berg, P. Lindgren224In the study by Green et al., 74 adult non-smokers with
moderate to severe asthma in a secondary care setting were
allocated to management either by standard BTS guidelines
or by normalisation of the induced sputum eosinophil count
and reduction of symptoms.14 Over the course of 1 year,
patients in the sputum management group had significantly
fewer severe exacerbations than patients in the BTS
management group (35 vs. 109; p ¼ 0.01) and were
hospitalised less frequently (one vs. six times; p ¼ 0.047).
There was no difference in the mean dose of ICS or oral
steroids between the two groups.
In a somewhat similar study, Jayaram et al. compared the
impact on the number and type of exacerbations of a
management strategy based on sputum cell counts against
clinical management in a sample of 102 adult non-smokers
with mild to severe asthma treated in secondary care.23 The
number of patients with exacerbations during the main-
tenance phase was significantly lower in the sputum strategy
group than in the clinical strategy group (52% vs. 71%;
p ¼ 0.04), using a similar mean cumulative dose of ICS. The
number of severe exacerbations was also significantly lower
in the sputum group (5 vs. 18; p ¼ 0.004), none of which
required hospitalisation.
Smith et al.26 compared the adjustment of ICS dose using
a treatment algorithm either based on FENO measurements
or on GINA guidelines in a group of 97 adults and adolescents
who were non-smokers in a primary care setting. There were
no statistically significant differences in exacerbation rates
or the number of affected patients between the two
management groups. However, the mean fluticasone doses
at the end of the maintenance phase were significantly
lower in the FENO group than in the GINA group (370 mg vs.
641 mg/day; p ¼ 0.003).Table 2 summarises the parameter values used for
baseline event probabilities and the impact of management
based on FENO on different outcomes. The proportion of
severe exacerbations requiring an outpatient visit and the
number of severe exacerbations overall were based on
results from the FACET study,28,29 which had mild and severe
exacerbations as a primary outcome. In the model, visits to
monitor asthma control based on FENO and standard guide-
lines were assumed to occur four times per year.21 The table
also shows the assumed distributions for the stochastic
sensitivity analysis.
In the base case analysis, the patient population is
assumed to correspond to the mild to severe population
seen in the study by Jayaram et al. Since there were no
hospitalisations in this study, only the risk reduction for
overall exacerbations is applied in the base case. A separate
scenario is run for moderate to severe patients, where the
risk reduction for hospitalisations observed in the study by
Green et al. is applied instead.Costs and utilities
Since the economic evaluation was performed from a payer
perspective and available data only assessed the change in
resource use, solely direct medical costs were included in
the analysis. These included the different diagnostic tests,
outpatient and inpatient visits as well as treatment costs. In
Germany, unit costs for tests and visits are based on
reimbursement tariffs. Drug costs were based on averages
across recommended dosing ranges and typical treatments
used for maintenance and rescue therapy. The costs and
sources for the different items are summarised in Table 3.
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Table 3 Unit costs used in the German asthma model.
Cost item h Source
Tests (per test)
NIOX MINO (FENO
measurement)
34* Aerocrine
Spirometry 8 EBM 2000plus,
2006
Reversibility test 22 EBM 2000plus,
2006
Bronchial provocation 106 EBM 2000plus,
2006
Sputum eosinophil
induction+count
106 EBM 2000plus,
2006
Spirometry+bronchoprovo-
cation
112 EBM 2000plus,
2006
Visits (per visit)
Outpatient visit to GP 17 EBM 2000plus,
2006
Outpatient visit to lung
specialist
23 EBM 2000plus,
2006
Hospitalisation due to
asthma
1643 Fallpauschalen-
katalog G-DRG,
2006
Treatment
Maintenance therapy with
long-acting b-agonist (1
year)
328 Gelbe Liste, 2006
Maintenance therapy with
inhaled steroid (1 year)
488 Gelbe Liste, 2006
Rescue therapy with short-
acting b-agonist (1 week)
5 Gelbe Liste, 2006
Rescue therapy with oral
prednisone (1 week)
9 Gelbe Liste, 2006
Note: *The expected reimbursement price of NIOX MINO in
Germany has been based on the average reimbursement
price from other international markets and is inclusive of the
equipment cost.
Economic evaluation of FENO measurement in asthma 225Utilities for different levels of asthma control were taken
from a study by Szende et al.30 They investigated health-
related QoL measured on the EQ-5D in a cross-sectional
study of 228 adult asthma patients receiving treatment.
Control was defined as good, mildly reduced, moderately
reduced and poor, based on the GINA guidelines. The EQ-5D
questionnaire is a generic, utility-based QoL instrument that
covers five health dimensions: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. Pa-
tients’ answers can be translated into utilities via an
algorithm developed for general population preferences.31
Asthma patients with good control had a utility value of
0.93, those with mildly reduced control 0.76, moderately
reduced control 0.65 and poor control 0.52.30 For our model,
we assumed successfully controlled patients to have good
control, those with an exacerbation not requiring hospita-
lisation to have moderately reduced control and those
requiring hospitalisation to have poor control. For thestochastic sensitivity analysis, the utilities were assumed
to be normally distributed, with an upper boundary of 1. The
standard deviation was assumed to have the same relation-
ship to the mean, implying a factor of 0.47, as found in an
overall sample of asthma patients in a population-based
study in Sweden.32Results
Cost-effectiveness results: base case
Diagnosis
Based on the assumptions outlined in the Methods section,
the outcomes for the base case of FENO measurement
compared with standard tests are calculated using the
decision tree outlined in Figure 1. Weighing together costs,
accuracy and relative frequency, asthma diagnosis based on
FENO measurement with NIOX MINO results in a cost of h38
per patient, compared with h26 for the set of standard
diagnostics. This includes the cost of false diagnoses and
additional outpatient visits resulting from these.Management
In mild to severe asthma patients seen in primary and
secondary care, management based on inflammation mon-
itoring with FENO measurement using NIOX MINO is cost-
saving compared with management based on standard
guidelines, i.e. measurement of lung function and b-agonist
use. Including outcomes such as ICS use and exacerbations,
patients managed with FENO measurement (NIOX MINO)
accrue a cost of h949 over the course of one year, compared
with h981 for patients with standard management. More-
over, asthma patients managed based on FENO levels have a
higher utility than those managed according to standard
guidelines, 0.781 compared with 0.726. The incremental
cost for management according to standard guidelines is h32
and the incremental effect 0.055 QALYs.Sensitivity analyses
Diagnosis
Table 4 summarises the results of sensitivity analyses on
various parameters in the diagnosis model and their impact
on the cost per test. In particular, the results were sensitive
to the reimbursement price of NIOX MINO. Since in clinical
practice FENO measurement may be added to existing lung
function tests, rather than replacing these, the cost of NIOX
MINO was added to that of spirometry, using the sensitivity
and specificity of the combination reported by Smith and
Taylor,20 resulting in an incremental cost of h18. When
comparing FENO measurement to bronchoprovocation and
spirometry, FENO measurement would be cost-saving.
To test possible uncertainty in the key clinical para-
meters, we conducted a second-order sensitivity analysis. To
this end, 1000 simulations were conducted, where values for
the sensitivity and specificity were drawn randomly from the
assumed underlying distributions. The mean incremental
cost of using NIOX MINO in asthma diagnosis is thus h12, with
a 95% confidence interval of (h9; h14).
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Table 4 Sensitivity analysis for selected parameters in diagnosis model.
Variation in model parameters Cost (h)
NIOX MINO Standard diagnostics Incremental cost
Variation in test sensitivity
50% 41 27 14
+10% 37 25 12
Variation in test specificity (standard: bronchoprovocation and sputum only)
50% 42 26 16
+10% 37 25 11
Asthma prevalence in tested population (base case: 36%)
10% 38 22 16
50% 37 27 10
90% 37 32 5
NIOX MINO cost (base case: h34)
50% 21 26 5
+50% 55 26 29
Cost of standard tests
+50% 38 36 2
+100% 38 46 9
+150% 38 57 19
+200% 38 67 30
Number of added visits for false diagnosis (base case: 1)
2 visits 41 30 11
4 visits 48 39 9
Scenarios
NIOX MINO+spirometry vs. Standard diagnostics 44 26 18
NIOX MINO vs. Bronchoprovocation+spirometry 38 106 68
NIOX MINO+spirometry vs. Bronchoprovocation+spirometry 44 106 62
Note: NIOX MINO corresponds to FENO measurement.
J. Berg, P. Lindgren226Management
We conducted a number of sensitivity analyses for all
relevant assumptions in the asthma management model,
most of which did not change the overall outcome of FENO
measurement being the dominant strategy (i.e. less costly
and with same or better effectiveness) over standard
management (see Table 5). The most important assumption
concerns the patient population analysed, which in the base
case was assumed to correspond to the mild to severe
population seen in the study by Jayaram et al.23 In a
sensitivity analysis, we assumed a more severe population as
in the study by Green et al.,22 applying a reduction in
hospitalisations instead of exacerbation rates (as the change
in severe exacerbations were not statistically significant at
p ¼ 0.05). This led to increased costs in the standard
management arm due to more hospitalisations and reduced
incremental utility in the FENO measurement arm, while
overall exacerbations were the same in both groups.
The follow-up period in the study by Jayaram et al. was
on average 1.5 years, which means that the proportion of
exacerbations observed (71%) could in fact be lower during
the 1-year period assumed in the model. We tested a
baseline risk of 35%, which was drawn from the 1-year FACETstudy.29 This led to decreased overall costs and improved
utilities, while FENO measurement remained dominant.
In an overall asthma population of varying severity, the
results are relatively sensitive to changes in the number of
visits (set to four per year in the base case) and the cost of
NIOX MINO and other resources. Due to the larger cost
margin seen in a more severe population because of the high
impact on hospitalisations, the results in this patient group
are more robust to changes in the above parameters.
Table 6 shows the results of sensitivity analyses on the
impact of management with FENO on ICS dose, exacerbation
risk and hospitalisation risk. Changes in the ICS dose
reduction or the relative risk reduction for exacerbations
with FENO measurement affected results in the overall
population. In a moderate–severe population, the results
are not sensitive to changes in ICS dose reduction, due to the
importance of hospitalisations in this patient group.
To test the uncertainty surrounding the model estimates,
a second-order stochastic sensitivity analysis was per-
formed. To this end, 1000 simulations were conducted,
where the parameters used in the model (baseline event
rates, risk reductions and utilities) were drawn at random
from their underlying distributions. The results from the
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Table 5 Sensitivity analysis for key baseline parameters in management model.
Cost (h) Incremental
cost (h)
Effect (QALY) Incremental
effect (QALY)
ICER (h/QALY)
Moderate–severe population
Standard guidelines 1109 0.726
NIOX MINO 948 161 0.730 0.004 Dominant
1-year baseline risk of exacerbation ¼ 0.35 (base case ¼ 0.71): overall population
Standard guidelines 914 0.830
NIOX MINO 847 67 0.857 0.027 Dominant
Number of monitoring visits per year:overall population (base case ¼ 4)
2 visits/year
Standard guidelines 965 0.726
NIOX MINO 881 84 0.781 0.055 Dominant
6 visits/year
Standard guidelines 998 0.726
NIOX MINO 1017 19 0.781 0.055 347
Number of monitoring visits per year: moderate–severe population (base case ¼ 4)
2 visits/year
Standard guidelines 1092 0.726
NIOX MINO 880 212 0.730 0.004 Dominant
6 visits/year
Standard guidelines 1125 0.726
NIOX MINO 1016 109 0.730 0.004 Dominant
NIOX MINO cost: overall population
50%
Standard guidelines 981 0.726
NIOX MINO 881 100 0.781 0.055 Dominant
+50%
Standard guidelines 981 0.726
NIOX MINO 1017 36 0.781 0.055 654
NIOX MINO cost: moderate–severe population
50%
Standard guidelines 1109 0.726
NIOX MINO 880 229 0. 730 0.004 Dominant
+50%
Standard guidelines 1109 0.726
NIOX MINO 1016 93 0.730 0.004 Dominant
Costs (except NIOX MINO): overall population
50%
Standard guidelines 491 0.726
NIOX MINO 543 52 0.781 0.055 945
+50%
Standard guidelines 1472 0.726
NIOX MINO 1356 116 0.781 0.055 Dominant
Costs (except NIOX MINO): moderate–severe population
50%
Standard guidelines 554 0.726
NIOX MINO 542 12 0.730 0.004 Dominant
+50%
Standard guidelines 1663 0.726
NIOX MINO 1355 308 0.730 0.004 Dominant
Notes: NIOX MINO corresponds to FENO measurement.
ICER ¼ incremental cost-effectiveness ratio.
QALY ¼quality-adjusted life-year.
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Table 6 Sensitivity analysis on effectiveness measures for FENO management.
Cost (h) Incremental
cost (h)
Effect (QALY) Incremental
effect (QALY)
ICER (h/QALY)
ICS dose reduction:overall population (base case ¼ 42%)
10%
Standard guidelines 981 0.726
NIOX MINO 1025 44 0.781 0.055 785
80%
Standard guidelines 981 0.726
NIOX MINO 860 121 0.781 0.055 Dominant
ICS dose reduction: moderate–severe population (base case ¼ 42%)
10%
Standard guidelines 1109 0.726
NIOX MINO 994 115 0.730 0.004 Dominant
80%
Standard guidelines 1109 0.726
NIOX MINO 895 214 0.730 0.004 Dominant
Relative risk reduction for exacerbation: overall population (base case ¼ 27%)
10%
Standard guidelines 981 0.726
NIOX MINO 997 16 0.747 0.021 743
50%
Standard guidelines 981 0.726
NIOX MINO 886 95 0.828 0.102 Dominant
Relative risk reduction for hospitalisation: moderate–severe population (base case ¼ 83%)
10%
Standard guidelines 1109 0.726
NIOX MINO 1127 18 0.727 0.001 37706
100%
Standard guidelines 1109 0.726
NIOX MINO 907 202 0.731 0.005 Dominant
Notes: NIOX MINO corresponds to FENO measurement.
ICER ¼ incremental cost-effectiveness ratio.
QALY ¼quality-adjusted life-year.
J. Berg, P. Lindgren228stochastic analysis are presented in the form of 95%
confidence intervals for the incremental costs and effects
in the two population types (Table 7). The fact that the
confidence intervals for the incremental effects are rela-
tively evenly spread around 0 illustrates the uncertainty
regarding the standard deviation of the utilities and the
relatively similar health benefits seen for the two alter-
natives in our model. Although the stochastic sensitivity
analysis illustrates the uncertainty of available information,
health economic decisions should be based on the mean net
benefits (i.e. mean incremental costs and effects), as the
objective is to maximise health gains within a given budget.
The distribution of net benefits should rather be used as an
indication of the value of acquiring additional information.33Discussion
This study has evaluated the cost-effectiveness of using FENO
measurement with NIOX MINO in the diagnosis and manage-
ment of asthma based on available clinical data. The resultsshow that, at a reimbursement price of h34, asthma
diagnosis based on FENO measurement alone costs h12 more
per patient than standard diagnostic methods, while
addition of FENO measurement to spirometry increases costs
by h18 per patient. In the management of asthma, the use of
FENO measurement with NIOX MINO in treatment decisions is
less costly and more effective than management based on
standard guidelines, both in a general asthma population
and in more severe patients. These results are independent
of the specific NO analysis technique used. Although it is not
possible to generate an overall cost-effectiveness ratio for
the use of FENO measurement in both asthma diagnosis and
management, because of different outcomes, the results
suggest that even if FENO measurement (NIOX MINO) were
added to standard methods in the diagnosis stage, the
incremental costs would be offset by savings through
optimisation of ICS use and reduction of exacerbations/
hospitalisations during the management process.
This is to our knowledge the first health economic
evaluation of a medical device in the diagnosis and
management of asthma. Previous economic studies have
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Table 7 Results of stochastic simulation for FENO measurement (NIOX MINO) in asthma management.
Incremental cost (h) Incremental effect (QALY)
Mean 95% CI Mean 95% CI
Mild–severe population 24 96 41 0.029 0.144 0.205
Moderate–severe population 110 297 26 0.003 0.017 0.025
Notes: NIOX MINO corresponds to FENO measurement.
CI ¼ confidence interval.
QALY ¼quality-adjusted life-year.
Economic evaluation of FENO measurement in asthma 229focused on drugs and treatment strategies. The cost per
patient and year for asthma management found in our study
can be compared with the results of a retrospective cross-
sectional cost-of-illness study of 500 asthma and rhinitis
patients in Germany.34 For adult patients with moderate or
severe asthma, the annual direct costs from a healthcare
payer perspective were between h900 and h1500, with costs
being somewhat higher for children. Costs covered in- and
outpatient visits, drugs and rehabilitation care, the latter
accounting for around 36% of direct medical costs. Con-
sidering that this item was not included in our model, these
figures match the annual cost of approximately h1000 for
management using standard guidelines found in our study.
Only a small number of studies have used utility measures
such as the EQ-5D to assess QoL in asthma. For our analysis
of asthma management, we have used, to our knowledge,
the only available data that links utilities to levels of asthma
control.30 Due to difficulties in assessing the impact of
exacerbations and hospitalisations on QoL, the allocation of
different utilities to levels of asthma control in our
management model can only be an approximation at this
stage. Moreover, as Szende et al. pointed out, the EQ-5D has
limited validity in patients with very mild asthma, and only
differences of 0.03 or more on the utility scale can be
observed. Therefore, the slight improvement in QALYs seen
in a moderate–severe population in our model is related to
significant uncertainty, and it is appropriate to say that FENO
measurement and spirometry offer similar health effects in
this population given the available data.
We did not include costs due to lost productivity in our
analysis, since there is no data on the direct impact of FENO
management on this parameter. However, inclusion of
indirect costs would likely improve the results further, since
it has been shown that exacerbations lead to several days off
work, on average, 3 days for mild exacerbations and 7 days
for severe exacerbations.28 Moreover, in the cross-sectional
cost-of-illness study for Germany, indirect costs accounted
for at least 50% of total costs per adult with moderate or
severe asthma.34
There are some limitations to our evaluation arising from
the available data. Since clinical data are inconclusive for
smokers, the diagnostic value of FENO is more limited in
these patients. Therefore, the effect of FENO management
on treatment outcomes is mainly based on studies in adult
non-smokers. Moreover, several population-based studies of
asthma have shown that raised FENO levels are related to
atopy and increased airway responsiveness, rather than
asthma per se (e.g. Refs.35,36). This is contrasted by
findings in patients with symptoms suggesting asthma,where high FENO levels (above 15 ppb) had a significant
association with clinical asthma (based on lung function
criteria) both in atopic and non-atopic patients.37 The latter
patient selection method dominates in the studies on the
accuracy and efficacy of FENO measurement that we used
and can be argued to represent the most likely setting for
this test in clinical practice. On the other hand, some of the
studies used for our analyses included a majority of patients
with atopy and/or asthma defined on the basis of airway
responsiveness. Overall, the existing evidence implies that
while FENO levels are higher in atopic patients, those studies
that were conducted in a clinical setting with both atopic
and non-atopic patients suggest that FENO is a useful marker
for diagnosis and management in both patient types.
The majority of the results for FENO measurement used in
our study have been derived using chemiluminescence NO
analysis techniques, which were the mainstay of NO analysis
until relatively recently. The NIOX MINO device used for our
analysis utilises electrochemical sensors, and has been
shown to produce comparable results to the NIOX de-
vice.15,38,39 The largest comparative study to date38 found a
statistically significant linear relationship between the
results obtained by the two systems in both asthmatics
and healthy volunteers regardless of steroid treatment.
Therefore, we think it is justified to apply the existing data
on accuracy and efficacy of FENO management to the NIOX
MINO device.
While the effect of FENO management on ICS dose is based
on patients treated in primary care,26 the impact on
exacerbations is drawn from populations managed in
secondary care.22,23 We have included both parameters in
the model, thus assuming a mixed population utilising both
primary and secondary care resources. In addition, the
results refer to a 1-year period following a run-in phase to
establish the minimum treatment required. Considering the
seasonal variations that can be seen in asthma, a longer
timeframe may be needed to assess stabilisation of control,
and thus the outcomes linked to different management
strategies.
In conclusion, this study has shown that from a German
healthcare payer perspective, FENO measurements with the
NIOX MINO device for the management of asthma is less
costly than standard methods while providing similar health
benefits. The cost savings are seen in the management of
patients with different severity levels, including a general
population and those with moderate to severe asthma. If
FENO measurement with NIOX MINO were to substitute or
complement standard tools in the diagnostic process, the
incremental cost would be offset by cost-savings during the
ARTICLE IN PRESS
J. Berg, P. Lindgren230management phase. Further research is needed on the
impact of correct and false diagnoses on asthma outcomes,
e.g., hospitalisations and drug use. Moreover, there is a need
for more data on the effect of FENO on patient outcomes,
e.g., measured in QALYs, in different patient populations
and care settings.
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